MX2021000401A - Nuevas proteinas de fusion especificas para cd137 y pd-l1. - Google Patents
Nuevas proteinas de fusion especificas para cd137 y pd-l1.Info
- Publication number
- MX2021000401A MX2021000401A MX2021000401A MX2021000401A MX2021000401A MX 2021000401 A MX2021000401 A MX 2021000401A MX 2021000401 A MX2021000401 A MX 2021000401A MX 2021000401 A MX2021000401 A MX 2021000401A MX 2021000401 A MX2021000401 A MX 2021000401A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- fusion protein
- compositions
- nucleic acid
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18186445 | 2018-07-31 | ||
| EP18204548 | 2018-11-06 | ||
| PCT/EP2019/070596 WO2020025659A1 (en) | 2018-07-31 | 2019-07-31 | Novel fusion protein specific for cd137 and pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000401A true MX2021000401A (es) | 2021-03-25 |
Family
ID=67480227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000401A MX2021000401A (es) | 2018-07-31 | 2019-07-31 | Nuevas proteinas de fusion especificas para cd137 y pd-l1. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20210363257A1 (https=) |
| EP (2) | EP4249064A3 (https=) |
| JP (1) | JP7482488B2 (https=) |
| KR (1) | KR20210040103A (https=) |
| CN (1) | CN112789292A (https=) |
| AU (1) | AU2019315703A1 (https=) |
| BR (1) | BR112020025263A2 (https=) |
| CA (1) | CA3100119A1 (https=) |
| CL (1) | CL2021000207A1 (https=) |
| CY (1) | CY1126148T1 (https=) |
| DK (1) | DK3830120T5 (https=) |
| ES (1) | ES2948717T3 (https=) |
| FI (1) | FI3830120T3 (https=) |
| HR (1) | HRP20230590T2 (https=) |
| HU (1) | HUE062320T2 (https=) |
| IL (1) | IL279541A (https=) |
| LT (1) | LT3830120T (https=) |
| MD (1) | MD3830120T3 (https=) |
| MX (1) | MX2021000401A (https=) |
| MY (1) | MY200710A (https=) |
| PH (1) | PH12021550001A1 (https=) |
| PL (1) | PL3830120T3 (https=) |
| RS (1) | RS64343B9 (https=) |
| SG (1) | SG11202100989UA (https=) |
| SI (1) | SI3830120T1 (https=) |
| TW (1) | TWI837156B (https=) |
| WO (1) | WO2020025659A1 (https=) |
| ZA (1) | ZA202100125B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019388808A1 (en) * | 2018-11-29 | 2021-06-17 | Harbour Biomed Therapeutics Limited | Anti-PD-L1 antibody preparation |
| AU2020253034A1 (en) * | 2019-03-29 | 2021-08-19 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| US11466086B2 (en) | 2019-10-11 | 2022-10-11 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding 4-1BB and uses thereof |
| AU2021285201A1 (en) | 2020-06-05 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1BB |
| WO2022082005A1 (en) * | 2020-10-16 | 2022-04-21 | Qlsf Biotherapeutics, Inc. | Multispecific binding compounds that bind to pd-l1 |
| CA3203718A1 (en) * | 2021-01-08 | 2022-07-14 | Jiawang Liu | Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
| CN115521379B (zh) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-1抗体及其用途 |
| CN115677858A (zh) * | 2021-07-23 | 2023-02-03 | 合肥瀚科迈博生物技术有限公司 | 一种能够靶向cd137和pd-l1的双特异性抗体的用途 |
| CN114736303A (zh) * | 2022-03-17 | 2022-07-12 | 英诺湖医药(杭州)有限公司 | 抗pd-l1和4-1bb的双功能抗体及其医药用途 |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| KR20250071257A (ko) * | 2022-09-21 | 2025-05-21 | 씨젠 인크. | Cd137 및 cd228에 특이적인 신규한 융합 단백질 |
| CN116211860B (zh) * | 2023-05-10 | 2023-08-22 | 细胞生态海河实验室 | Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CZ298681B6 (cs) | 1998-06-08 | 2007-12-19 | F. Hoffmann-La Roche Ag | Lécivo pro lécení infekcí chronické hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| KR20170138574A (ko) * | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | 항암 융합 폴리펩타이드 |
| KR102734408B1 (ko) * | 2015-05-04 | 2024-11-27 | 피어이스 파마슈티컬즈 게엠베하 | Cd137에 특이적인 신규한 단백질 |
| MX390894B (es) * | 2015-05-18 | 2025-03-21 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anti-cáncer. |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| JP6432121B2 (ja) * | 2016-03-04 | 2018-12-05 | シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド | Ｐｄｌ−１抗体、その医薬組成物及びその使用 |
| CN108350082B (zh) | 2016-06-13 | 2021-09-24 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CN107082812B (zh) * | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
| KR102678252B1 (ko) * | 2017-09-01 | 2024-06-26 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 재조합 이중특이적 항체 |
| WO2023000675A1 (zh) * | 2021-07-23 | 2023-01-26 | 安徽安科生物工程（集团）股份有限公司 | 靶向pd-l1和4-1bb的双特异性抗体 |
-
2019
- 2019-07-31 CA CA3100119A patent/CA3100119A1/en active Pending
- 2019-07-31 SI SI201930558T patent/SI3830120T1/sl unknown
- 2019-07-31 MD MDE20210513T patent/MD3830120T3/ro unknown
- 2019-07-31 EP EP23167877.2A patent/EP4249064A3/en active Pending
- 2019-07-31 JP JP2021529519A patent/JP7482488B2/ja active Active
- 2019-07-31 US US17/264,080 patent/US20210363257A1/en not_active Abandoned
- 2019-07-31 HU HUE19746089A patent/HUE062320T2/hu unknown
- 2019-07-31 LT LTEPPCT/EP2019/070596T patent/LT3830120T/lt unknown
- 2019-07-31 RS RS20230461A patent/RS64343B9/sr unknown
- 2019-07-31 TW TW108127283A patent/TWI837156B/zh not_active IP Right Cessation
- 2019-07-31 HR HRP20230590TT patent/HRP20230590T2/hr unknown
- 2019-07-31 EP EP19746089.2A patent/EP3830120B9/en active Active
- 2019-07-31 WO PCT/EP2019/070596 patent/WO2020025659A1/en not_active Ceased
- 2019-07-31 BR BR112020025263-8A patent/BR112020025263A2/pt unknown
- 2019-07-31 ES ES19746089T patent/ES2948717T3/es active Active
- 2019-07-31 DK DK19746089.2T patent/DK3830120T5/da active
- 2019-07-31 MY MYPI2020006434A patent/MY200710A/en unknown
- 2019-07-31 PL PL19746089.2T patent/PL3830120T3/pl unknown
- 2019-07-31 KR KR1020217006003A patent/KR20210040103A/ko not_active Ceased
- 2019-07-31 CN CN201980050587.8A patent/CN112789292A/zh active Pending
- 2019-07-31 AU AU2019315703A patent/AU2019315703A1/en not_active Abandoned
- 2019-07-31 SG SG11202100989UA patent/SG11202100989UA/en unknown
- 2019-07-31 MX MX2021000401A patent/MX2021000401A/es unknown
- 2019-07-31 FI FIEP19746089.2T patent/FI3830120T3/fi active
-
2020
- 2020-12-17 IL IL279541A patent/IL279541A/en unknown
-
2021
- 2021-01-01 PH PH12021550001A patent/PH12021550001A1/en unknown
- 2021-01-07 ZA ZA2021/00125A patent/ZA202100125B/en unknown
- 2021-01-26 CL CL2021000207A patent/CL2021000207A1/es unknown
-
2023
- 2023-06-29 CY CY20231100305T patent/CY1126148T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000401A (es) | Nuevas proteinas de fusion especificas para cd137 y pd-l1. | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| ZA202104287B (en) | Novel fusion proteins specific for cd137 and gpc3 | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| CL2021002094A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153) | |
| MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| DOP2017000191A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| CL2022000664A1 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| CR11817A (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
| AR112069A1 (es) | Inmunoglobulinas que fijan aggrecan | |
| MX2019014397A (es) | Polipeptidos que enlazan adamts5, mmp13 y agrecano. | |
| MX2025006169A (es) | Inmunoglobulinas de enlace a mmp13 | |
| AR095387A1 (es) | Proteínas específicas para el baff y para la b7rp1 y sus usos | |
| BR112017024714A2 (pt) | métodos para preparação do fator de von willebrand modificado | |
| CO2025003722A2 (es) | Nueva proteína de fusión específica para cd137 y cd228 | |
| AR115878A1 (es) | Proteínas de fusión específicas para cd137 y pd-l1 | |
| AR127728A1 (es) | Nueva proteína de fusión específica para ox40 y pd-l1 | |
| BR112017020008A8 (pt) | Peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele | |
| MX2022002774A (es) | Método de captura y purificación de productos biológicos. | |
| MX2021009767A (es) | Moleculas de union de fmcr y usos de las mismas. | |
| EA202092606A1 (ru) | Новый слитый белок, специфичный к cd137 и pd-l1 | |
| BR112018016281A2 (pt) | molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo |